Amgen analyst likes diversified business, remains patient until MariTide obesity data
Amgen Inc. AMGN shares are trading close to its 52-week high on Wednesday after the company reported better-than-expected ...
Model output · Signal date 2026-11-06
Amgen Inc (AMGN) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
of 5150 stocks scored
Rank correlation · 90D
-1.0%
Spearman, 357 dates
Market Cap
$248.92B
mega-cap · #1 of 60 peers
Summary
Amgen Inc (AMGN) stock forecast summary
Our AI scores Amgen Inc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Amgen Inc is a mega-cap company with a market capitalization of $248.92B. It ranks number 1 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast. Its ROE of 65.4% is the highest of the 43 peers that report one. Its D/E Ratio of 5.69x is the highest of the 51 peers that report one.
For AMGN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -1.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -5.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, AMGN included.
Price
AMGN price chart and AI forecast
Cross-section · 2026-11-06
How AMGN ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-09-30
Amgen Inc (AMGN) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | AMGN | Rank |
|---|---|---|
| Market Cap | $248.92B | 1/60 |
| P/E Ratio | 26.71x | 8/16 |
| P/B Ratio | 17.34x | 8/48 |
| Dividend Yield | 2.16% | – |
| EPS | $17.24 | – |
| Book Value/Share | $26.55 | – |
| Revenue/Share | $71.96 | – |
| FCF/Share | $17.72 | – |
Profitability & Margins
| Metric | AMGN | Rank |
|---|---|---|
| ROE | 65.4% | 1/43 |
| ROA | 9.8% | 9/46 |
| ROIC | 17.3% | 8/52 |
| Gross Margin | 70.9% | 13/23 |
| Operating Margin | 32.4% | 7/40 |
| Net Margin | 24.1% | 6/35 |
| EBT Margin | 28.4% | 7/42 |
| Tax Rate | 15.0% | – |
Financial Health
| Metric | AMGN | Rank |
|---|---|---|
| Current Ratio | 1.48x | 58/59 |
| Quick Ratio | 1.20x | 28/29 |
| D/E Ratio | 5.69x | 1/51 |
| Financial Leverage | 6.69x | 1/50 |
| Interest Coverage | 5.7x | 11/37 |
| Working Capital | $11.13B | 2/58 |
Cash Flow
| Metric | AMGN | Rank |
|---|---|---|
| Operating Cash Flow | $12.04B | 3/56 |
| Free Cash Flow | $9.58B | 3/49 |
| Capital Spending | -$2.45B | 49/49 |
| OCF Growth YoY | -8.3% | 12/16 |
| FCF Growth YoY | -17.0% | 14/16 |
| FCF/Sales | 24.6% | 10/32 |
| CapEx/Sales | 6.3% | 11/32 |
Operational Efficiency
| Metric | AMGN | Rank |
|---|---|---|
| Asset Turnover | 0.41x | 16/37 |
| Receivables Turnover | 3.8x | 15/23 |
| Inventory Turnover | 1.8x | 16/22 |
| Fixed Assets Turnover | 4.4x | 19/38 |
| Days Sales Outstanding | 97 days | 9/23 |
| Days Inventory | 206 days | 7/22 |
| Payables Period | 95 days | 10/25 |
| Cash Conversion Cycle | 208 days | 5/17 |
Income Statement
| Metric | AMGN | Rank |
|---|---|---|
| Total Revenue | $38.90B | 1/38 |
| Operating Income | $12.61B | 1/53 |
| Net Income | $9.39B | 2/46 |
| R&D Expense | $7.84B | 2/55 |
| SG&A Expense | $6.98B | 1/23 |
| Cost of Goods Sold | $11.32B | 1/26 |
Dividend & Shareholder Information
| Metric | AMGN | Rank |
|---|---|---|
| Dividends Per Share | $9.93 | – |
| Payout Ratio | 57.6% | – |
| Shares Outstanding | 541M | – |
| Net Income Growth | 34.1% | 5/11 |
| EPS Growth | 35.3% | 5/14 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $34.36B | 35.8% of assets |
| Cash & Short-term Investments | $13.19B | 13.7% of assets |
| Accounts Receivable | $10.35B | 10.8% of assets |
| Inventory | $6.39B | 6.7% of assets |
| Total Liabilities | $81.70B | 85.1% of assets |
| Short-term Debt | $20.29B | 21.1% of assets |
Quarterly Financial Reports
AMGN quarterly financials and insider trading
Industry Peers · Biological Products, (No Diagnostic Substances)
Amgen Inc (AMGN) industry peers
Companies classified under the same SEC industry code as Amgen Inc (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| AMGN Amgen Inc | $248.92B | |
| GILD Gilead Sciences, Inc. | $207.00B | |
| MRNA Moderna, Inc. | $101.48B | |
| ARGX Argenx Se | $57.38B | |
| RVMD Revolution Medicines, Inc. | $38.08B | |
| BIIB Biogen Inc. | $36.71B | |
| BNTX Biontech Se | $22.13B | |
| EXEL Exelixis, Inc. | $16.98B | |
| NBIX Neurocrine Biosciences Inc | $16.73B | |
| HALO Halozyme Therapeutics, Inc. | $11.76B | |
| TECH Bio-Techne Corp | $11.43B | |
| KYMR Kymera Therapeutics, Inc. | $11.25B | |
| RGEN Repligen Corp | $11.09B | |
| QGEN Qiagen N.V. | $10.92B | |
| PCVX Vaxcyte, Inc. | $9.51B | |
| IBRX Immunitybio, Inc. | $9.15B | |
| KRYS Krystal Biotech, Inc. | $8.92B | |
| TWST Twist Bioscience Corp | $7.57B | |
| CGON Cg Oncology, Inc. | $6.74B | |
| IMVT Immunovant, Inc. | $6.31B | |
| KOD Kodiak Sciences Inc. | $6.24B | |
| SRRK Scholar Rock Holding Corp | $5.54B | |
| CRSP Crispr Therapeutics Ag | $4.84B | |
| ADPT Adaptive Biotechnologies Corp | $4.47B | |
| RLAY Relay Therapeutics, Inc. | $4.08B | |
| IOVA Iovance Biotherapeutics, Inc. | $3.64B | |
| TARS Tarsus Pharmaceuticals, Inc. | $3.33B | |
| DNLI Denali Therapeutics Inc. | $3.21B | |
| ADMA Adma Biologics, Inc. | $2.85B | |
| BEAM Beam Therapeutics Inc. | $2.73B | |
| VCEL Vericel Corp | $2.65B | |
| COAG Hemab Therapeutics Holdings, Inc. | $2.29B | |
| RXRX Recursion Pharmaceuticals, Inc. | $2.18B | |
| LIFE Atyr Pharma Inc | $2.14B | |
| REPL Replimune Group, Inc. | $2.05B | |
| BCRX Biocryst Pharmaceuticals Inc | $1.97B | |
| MAZE Maze Therapeutics, Inc. | $1.90B | |
| VIR Vir Biotechnology, Inc. | $1.86B | |
| MESO Mesoblast Ltd | $1.83B | |
| NVAX Novavax Inc | $1.78B | |
| ALVO Alvotech | $1.73B | |
| IMCR Immunocore Holdings Plc | $1.60B | |
| TSHA Taysha Gene Therapies, Inc. | $1.41B | |
| VOR Vor Biopharma Inc. | $1.15B | |
| ODTX Odyssey Therapeutics, Inc. | $924M | |
| GLUE Monte Rosa Therapeutics, Inc. | $902M | |
| IMTX Immatics N.V. | $853M | |
| PRME Prime Medicine, Inc. | $843M | |
| MGTX Meiragtx Holdings Plc | $817M | |
| DNA Ginkgo Bioworks Holdings, Inc. | $760M | |
| CGEM Cullinan Therapeutics, Inc. | $728M | |
| SANA Sana Biotechnology, Inc. | $709M | |
| SLDB Solid Biosciences Inc. | $707M | |
| AURA Aura Biosciences, Inc. | $680M | |
| FDMT 4d Molecular Therapeutics, Inc. | $676M | |
| CADL Candel Therapeutics, Inc. | $670M | |
| DBVT Dbv Technologies S.A. | $657M | |
| SRZN Surrozen, Inc./De | $542M | |
| ENTX Entera Bio Ltd. | $518M | |
| SLBT Sl Science Holding Ltd | $513M |
Where AMGN sits on the market map
Life Sciences · Biological Products, (No Diagnostic Substances)
News
Amgen Inc (AMGN) stock news
Amgen, AstraZeneca drug combo shows promising survival results in tough-to-treat lung cancer
Amgen Inc. AMGN on Saturday released interim Phase 3 trial results showing that Imdelltra, evaluated in combination with ...
Amgen Inc. stock underperforms Thursday when compared to competitors
Amgen Inc. closed 4.60% short of its 52-week high of $482.48, which the company achieved on November 4th. Supported by world-class markets data from Dow Jones and FactSet, and partnering with ...
FAQ
Amgen Inc (AMGN) stock forecast FAQ
What is the Amgen Inc (AMGN) stock forecast?
Our AI scores Amgen Inc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Amgen Inc stock predictions?
For AMGN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -1.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -5.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Amgen Inc forecasts updated?
Amgen Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Amgen Inc's industry peers?
60 issuers in our coverage, AMGN included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB), Biontech Se (BNTX).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.